CCCC PE Ratio & Valuation,Is CCCC Overvalued

CCCC Relative Valuation

CCCC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CCCC is overvalued; if below, it's undervalued.

Historical Valuation

C4 Therapeutics Inc (CCCC) is now in the Fair zone, suggesting that its current forward PS ratio of 5.01 is considered Fairly compared with the five-year average of -6.22. The fair price of C4 Therapeutics Inc (CCCC) is between 1.53 to 20.81 according to relative valuation methord.

Relative Value

Fair Zone

1.53-20.81

Current Price：2.22

Fair

-1.37

0.26

EV/EBITDA

C4 Therapeutics Inc. (CCCC) has a current EV/EBITDA of 0.26. The 5-year average EV/EBITDA is -4.62. The thresholds are as follows: Strongly Undervalued below -17.80, Undervalued between -17.80 and -11.21, Fairly Valued between 1.97 and -11.21, Overvalued between 1.97 and 8.56, and Strongly Overvalued above 8.56. The current Forward EV/EBITDA of 0.26 falls within the Historic Trend Line -Fairly Valued range.

0.23

EV/EBIT

C4 Therapeutics Inc. (CCCC) has a current EV/EBIT of 0.23. The 5-year average EV/EBIT is -3.91. The thresholds are as follows: Strongly Undervalued below -15.71, Undervalued between -15.71 and -9.81, Fairly Valued between 1.99 and -9.81, Overvalued between 1.99 and 7.89, and Strongly Overvalued above 7.89. The current Forward EV/EBIT of 0.23 falls within the Historic Trend Line -Fairly Valued range.

5.01

C4 Therapeutics Inc. (CCCC) has a current PS of 5.01. The 5-year average PS is 29.41. The thresholds are as follows: Strongly Undervalued below -24.94, Undervalued between -24.94 and 2.23, Fairly Valued between 56.59 and 2.23, Overvalued between 56.59 and 83.77, and Strongly Overvalued above 83.77. The current Forward PS of 5.01 falls within the Historic Trend Line -Fairly Valued range.

-1.97

P/OCF

C4 Therapeutics Inc. (CCCC) has a current P/OCF of -1.97. The 5-year average P/OCF is -7.76. The thresholds are as follows: Strongly Undervalued below -23.76, Undervalued between -23.76 and -15.76, Fairly Valued between 0.24 and -15.76, Overvalued between 0.24 and 8.23, and Strongly Overvalued above 8.23. The current Forward P/OCF of -1.97 falls within the Historic Trend Line -Fairly Valued range.

-1.36

P/FCF

C4 Therapeutics Inc. (CCCC) has a current P/FCF of -1.36. The 5-year average P/FCF is -6.70. The thresholds are as follows: Strongly Undervalued below -21.17, Undervalued between -21.17 and -13.94, Fairly Valued between 0.53 and -13.94, Overvalued between 0.53 and 7.77, and Strongly Overvalued above 7.77. The current Forward P/FCF of -1.36 falls within the Historic Trend Line -Fairly Valued range.

C4 Therapeutics Inc (CCCC) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 1.09 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 2.21, the current P/B ratio is about -100.00% higher. C4 Therapeutics Inc (CCCC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -51.59%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -33.67% , the current FCF yield is about -100.00% lower.

0.00

P/B

Median3y

1.09

Median5y

2.21

0.00

FCF Yield

Median3y

-51.59

Median5y

-33.67

Competitors Valuation Multiple

The average P/S ratio for CCCC's competitors is 7.12, providing a benchmark for relative valuation. C4 Therapeutics Inc Corp (CCCC) exhibits a P/S ratio of 5.01, which is -29.73% above the industry average. Given its robust revenue growth of 138.17%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CCCC decreased by 36.02% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.04M to 7.24M.

The secondary factor is the Margin Expansion, contributed -61.03%to the performance.

Overall, the performance of CCCC in the past 1 year is driven by Revenue Growth. Which is more sustainable.

138.17%

3.04M → 7.24M

Revenue Growth

-61.03%

-933.23 → -363.66

Margin Expansion

-113.16%

0.00 → 0.00

P/E Change

-36.02%

3.47 → 2.22

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is C4 Therapeutics Inc (CCCC) currently overvalued or undervalued?

What is C4 Therapeutics Inc (CCCC) fair value?

CCCC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of C4 Therapeutics Inc (CCCC) is between 1.53 to 20.81 according to relative valuation methord.

How does CCCC's valuation metrics compare to the industry average?

What is the current P/B ratio for C4 Therapeutics Inc (CCCC) as of Jan 08 2026?

As of Jan 08 2026, C4 Therapeutics Inc (CCCC) has a P/B ratio of 0.00. This indicates that the market values CCCC at 0.00 times its book value.

What is the current FCF Yield for C4 Therapeutics Inc (CCCC) as of Jan 08 2026?

As of Jan 08 2026, C4 Therapeutics Inc (CCCC) has a FCF Yield of 0.00%. This means that for every dollar of C4 Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for C4 Therapeutics Inc (CCCC) as of Jan 08 2026?

As of Jan 08 2026, C4 Therapeutics Inc (CCCC) has a Forward P/E ratio of -1.37. This means the market is willing to pay $-1.37 for every dollar of C4 Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for C4 Therapeutics Inc (CCCC) as of Jan 08 2026?

As of Jan 08 2026, C4 Therapeutics Inc (CCCC) has a Forward P/S ratio of 5.01. This means the market is valuing CCCC at $5.01 for every dollar of expected revenue over the next 12 months.

CCCC Valuation